期刊文献+

2型糖尿病患者胰岛素抵抗与非酒精性脂肪肝的关系研究 被引量:1

Study on Relationship between Insulin Resistance and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的探讨2型糖尿病患者胰岛素抵抗指数与非酒精性脂肪肝的关系。方法检测54名确诊为2型糖尿病合并非酒精性脂肪肝患者的空腹血糖(FPG)、空腹血清胰岛素(FInS)、三酰甘油(TG)、胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)等指标,计算胰岛素抵抗指数(HOMA-IR),并与38例单纯2型糖尿病患者作对照。结果 2型糖尿病伴非酒精性脂肪肝病患者的FPG、FInS、HOMA-IR、TC、TG、LDL均显著高于对照组,差异有统计学意义(P<0.05或P<0.01)。结论型糖尿病伴非酒精性脂肪肝患者存在明显的胰岛素抵抗和脂代谢紊乱。控制血糖、改善胰岛素抵抗及脂代谢紊乱对预防和治疗2型糖尿病伴发非酒精性脂肪肝具有重要意义。 Objective To investigate the relationship between insulin resistance and non-alcoholic fatty liver disease(NAFLD)in patients with type 2 diabetes mellitus(T2DM).Methods The levels of fasting plasma glucoes(FPG),fasting insulin(FInS),triglycerides(TG),total cholesterol(TC),high density lipoprotein(HDL) and low density lipoprotein(LDL) were detected,the insulin resistance index(HOMA – IR) was calculated in 54 diagnosed patients with T2DM and NAFLD,and compared with 38 diagnosed patients with T2DM without NAFLD.Results The levels of plasma FPG,FInS,HOMA – IR,TG,TC,LDL in patients with T2DM and NAFLD were significantly higher than the control group(P0.05 or P0.01).Conclusion There are significant insulin resistance and lipid metabolic disorder in patients with T2DM and NAFLD.It is necessary to take measures to control the patient's blood sugar,reduce insulin resistance and improve lipid metabolism for the prevention and treatment of DAFLD in T2DM.
作者 李小飞 陈宇
出处 《中国医药指南》 2010年第36期23-24,共2页 Guide of China Medicine
关键词 2型糖尿病 胰岛素抵抗 非酒精性脂肪肝 Type 2 diabetes mellitus Insulin resistance Non-alcoholic fatty liver disease
  • 相关文献

参考文献10

  • 1Kotronen A,Yki-Jarvinen H,M nnist S,et al.Non-alcoholic and alcoholic Fatty Liver Disease -two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes:the FIN-D2D Survey[J].BMC Public Health,2010,10:237.
  • 2Heikkinen SAuwerx J Argmann CA.PPAR Y in human and mouse physiology[J].Biochim Biophys Acta,2007,1771(8):999-1013.
  • 3Sanyal AJ,Chalasani N,Kowdley KV,et al.Pioglitazone,Vitamin E.or Placebo for Nonalcoholic Steatohepatitis[J].N Engl J Med,2010,362(18):1675-1685.
  • 4Targher G,Bertolini L,Rodella S,et al.Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients[J].Diabetes Care,2007,30(8):2119-2121.
  • 5Akbar DH,Kawther AH.Nonalcoholic fatty Iiver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic,prevalence and general characteristics[J].Diabetes Care,2003,26(12):3351-3352.
  • 6Koh JH,Shin YG,Nam SM,et al.Serum Adipocyte Fatty AcidBinding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients[J].Diabetes Care,2009,32(1):147-152.
  • 7Shibata M,Kihara Y,Taguchi M,et al.Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men[J].Diabetes Care,2007,30(11):2940-2944.
  • 8Chitturi S,Farrell GC.Hashimoto E,et al.Non-alcoholic fatty liver disease in the Asia-Pacific region:definitions and overview of proposed guidelines[J].J Gastroenterol Hepatol,2007.22(6):778-787.
  • 9Erickson SK.Nonalcoholic fatty liver disease[J].J Lipid Res,2009,50(Suppl):S412-S416.
  • 10Paschos P,Paletas K Non alcoholic fatty liver disease and metabolic syndrome[J].Hippokratia,2009,13 (1):9-19.

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部